Drug Profile
Leuprorelin - Foresee Pharmaceuticals/ScinoPharma
Alternative Names: Camcevi; FP-001; FP-001 LMIS; FP-001/LMIS; leuprolide controlled-release - Foresee/ScinoPharma; Leuprolide Mesylate - Foresee/ScinoPharma; Leuprolide mesylate injectable suspension - Foresee Pharmaceuticals; LMIS - Foresee PharmaceuticalsLatest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Foresee Pharmaceuticals - ScinoPharm (JV)
- Developer Foresee Pharmaceuticals - ScinoPharm (JV); GeneScience Pharmaceuticals
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
- Phase III Precocious puberty